The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
US clinical-stage biotech Zura Bio on Thursday announced the appointment of Robert Lisicki as chief executive (CEO), effective April 8, 2024. 29 March 2024
The US Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for govorestat (AT-007) as a treatment of classic galactosemia by three months. 29 March 2024
Just as MDMA looked to be leading the charge of psychedelics and related compounds towards market for mental health conditions, a dose of jeopardy has been thrown into the mix. 28 March 2024
US biotech major Gilead Sciences today announced an exclusive license agreement with Xilio Therapeutics to develop and commercialize Xilio’s Phase I tumor-activated interleukin (IL)-12 program, XTX301. 28 March 2024
Cell therapy company Gamida Cell will be forced to go private after failing to find a partner for its cell therapy product Omisirge (omidubicel-onlv), which won US approval a year ago. 28 March 2024
The US Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. 28 March 2024
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved the use of Adzynma (apadamtase alfa/cinaxadamtase alfa; code name TAK-755) for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) for individuals 12 years of age and older. 28 March 2024
Swedish biotech Oncopeptides yesterday announced a collaboration with Vector Pharma FZCO to commercialize its flagship drug Pepaxti (melphalan flufenamide in the Middle East and North Africa (MENA) region. 28 March 2024
Dutch contract development and manufacturing organization (CDMO) Intravacc and Primrose Bio, a private US biotech developing discovery and production systems for protein and nucleic acid medicines, have announced a strategic partnership. 28 March 2024
Shares of US mRNA specialist Moderna closed up 3.2% at $110.59 yesterday, on the news that fund manager Blackstone Life Sciences will provide up to $750 million to fund Moderna’s influenza (flu) program. 28 March 2024
US biotech bluebird bio revealed that it had made mistakes in previous financial statements in a filing with the US Securities and Exchange Commission. 27 March 2024
An attempt from the conservative Alliance for Hippocratic Medicine to ban mifepristone, a medicine used to induce an abortion, threatens to undermine confidence in the American regulatory regime. 27 March 2024
California, USA-based clinical-stage biopharmaceutical company 89bio saw its shares gain more than 2% to $11.44 today, after it announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) status to pegozafermin in patients with metabolic-associated steatohepatitis (MASH). 27 March 2024
A South Korean clinical stage biotech, Bridge Biotherapeutic), has entered into a research collaboration with the University of Colorado School of Medicine. 27 March 2024
USA-based Praxis Precision Medicines, a biopharma translating genetic insights into therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, closed 21% up after Tuesday’s trading. 27 March 2024
A South Korean company, AriBio, has announced the signing of exclusive marketing rights for its investigational Alzheimer’s disease drug, AR1001. 27 March 2024
In what is seen as an important win for Merck & Co, the US pharma giant late yesterday announced that the US Food and Drug Administration (FDA) has approved sotatercept-csrk injection (which will be marketed in the USA as Winrevair). 27 March 2024